Shun-Ichi Nagata

Shun-Ichi Nagata

Auto-generated profile, based on publicly available information

Shun-Ichi Nagata

Genetic Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsurutamachi, Utsunomiya 320-0851, Tochigi, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2019 in Genes
Verified
Journal Article
Open access
PDF file
Teruaki TozakiTeruaki Tozaki
Teruaki Tozaki
AOAoi Ohnuma
Aoi Ohnuma
MTMasaki Takasu
Masaki Takasu
MKMIO KIKUCHI
MIO KIKUCHI
HKHironaga Kakoi
Hironaga Kakoi
SNShun-Ichi Nagata
Shun-Ichi Nagata
Indiscriminate genetic manipulation to improve athletic ability is a major threat to human sports and the horseracing industry, in which methods involving gene-doping, such as transgenesis, should be prohibited to ensure fairness. Therefore, development of methods to detect indiscriminate genetic manipulation are urgently needed. Here, we developed a highly sensitive method to detect horse erythropoietin (EPO) transgenes using droplet digital PCR (ddPCR). We designed two TaqMan probe/primer sets, and the EPO transgene was cloned into a plasmid for use as a model. We extracted the spiked EPO transgene from horse plasma and urine via magnetic beads, followed by ddPCR amplification for absolute quantification and transgene detection. The results indicated high recovery rates (at least ~60% and ~40% in plasma and urine, respectively), suggesting successful detection of the spiked transgene at concentrations of >130 and 200 copies/mL of plasma and urine, respectively. Additionally, successful detection was achieved following intramuscular injection of 20 mg of the EPO transgene. This represents the first study demonstrating a method for detecting the EPO transgene in horse plasma and urine, with our results demonstrating its efficacy for promoting the control of gene-doping in the horseracing industry.

23 April 2020 in Genes
Verified
Journal Article
Open access
PDF file
Teruaki TozakiTeruaki Tozaki
Teruaki Tozaki
AOAoi Ohnuma
Aoi Ohnuma
MKMIO KIKUCHI
MIO KIKUCHI
TITaichiro Ishige
Taichiro Ishige
HKHironaga Kakoi
Hironaga Kakoi
SNShun-Ichi Nagata
Shun-Ichi Nagata
Gene doping, an activity which abuses and misuses gene therapy, is a major concern in sports and horseracing industries. Effective methods capable of detecting and monitoring gene doping are urgently needed. Although several PCR-based methods that detect transgenes have been developed, many of them focus only on a single transgene. However, numerous genes associated with athletic ability may be potential gene-doping material. Here, we developed a detection method that targets multiple transgenes. We targeted 12 genes that may be associated with athletic performance and designed two TaqMan probe/primer sets for each one. A panel of 24 assays was prepared and detected via a microfluidic quantitative PCR (MFQPCR) system using integrated fluidic circuits (IFCs). The limit of detection of the panel was 6.25 copy/μL. Amplification-specificity was validated using several concentrations of reference materials and animal genomic DNA, leading to specific detection. In addition, target-specific detection was successfully achieved in a horse administered 20 mg of the EPO transgene via MFQPCR. Therefore, MFQPCR may be considered a suitable method for multiple-target detection in gene-doping control. To our knowledge, this is the first application of microfluidic qPCR (MFQPCR) for gene-doping control in horseracing.

10 October 2018 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
Teruaki TozakiTeruaki Tozaki
Teruaki Tozaki
SGShiori Gamo
Shiori Gamo
MTMasaki Takasu
Masaki Takasu
MKMIO KIKUCHI
MIO KIKUCHI
HKHironaga Kakoi
Hironaga Kakoi
SNShun-Ichi Nagata
Shun-Ichi Nagata
Doping control is an important and indispensable aspect of fair horse racing; genetic doping has been recently included to this. In this study, we aimed to develop a detection method of gene doping. A plasmid cloned with human erythropoietin gene (p.hEPO, 250 μg/head) was intramuscularly injected into a microminipig. Subsequently, p.hEPO was extracted from 1 mL of plasma and detected by droplet digital polymerase chain reaction. The results confirmed that the maximum amount of plasmid was detected at 15 min after administration and the majority of the plasmid was degraded in the bloodstream within 1–2 days after administration. In contrast, low amounts of p.hEPO were detected at 2–3 weeks after administration. These results suggest that the proposed method to detect gene doping can help obtain information for experiments using horses.

29 October 2018 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
Teruaki TozakiTeruaki Tozaki
Teruaki Tozaki
KKKaoru Karasawa
Kaoru Karasawa
YMYohei Minamijima
Yohei Minamijima
HIHideaki Ishii
Hideaki Ishii
MKMIO KIKUCHI
MIO KIKUCHI
SNShun-Ichi Nagata
Shun-Ichi Nagata
Clinical research on gene therapy has advanced the field of veterinary medicine, and gene doping, which is the illegal use of gene therapy, has become a major concern in horseracing. Since the International Federation of Horseracing Authorities defined the administration of oligonucleotides and its analogues as a genetic therapy in 2017, the development of therapeutic nucleotide-detection techniques has become an urgent need. Most currently marketed and developed oligonucleotide therapeutics for humans consist of modified nucleotides to increase stability, and phosphorothioate (PS) modification is common. We demonstrated the specific detection of phosphorothioated oligonucleotides (PSOs) using LC/MS/MS. PSOs produce the specific product ion (m/z 94.9362) derived from PS moiety. PS is not derived from endogenous substances in animal body, and the product ion is a suitable marker for the detection of PSOs. With our strategy, reproducible target analyses were achieved for identifying the specific substances, with a LOD of 0.1 ng/mL and a quantification rage of 0.1–200 ng/mL in deproteinated plasma. Non-target analyses could also detect the presence of PSOs selectively with 100 ng/mL in the same matrix. These results suggested that the detection of PSOs in horse blood is possible by targeting the product ion using LC/MS/MS.

1 September 2010 in American Journal of Veterinary Research
Verified
Journal Article
Closed access
SNShun-Ichi Nagata
Shun-Ichi Nagata
SYShozo Yamashita
Shozo Yamashita
MKMasahiko Kurosawa
Masahiko Kurosawa
MKMasao Kuwajima
Masao Kuwajima
SHSeiji Hobo
Seiji Hobo
TAToru Anzai
Toru Anzai
Objective—To determine the pharmacokinetics and tissue distribution of minocycline in horses. Animals—5 healthy Thoroughbred mares for the pharmacokinetic experiment and 6 healthy Thoroughbred mares for the tissue distribution experiment. Procedures—Each mare was given 2.2 mg of minocycline hydrochloride/kg, IV. Blood samples were collected once before minocycline administration (0 hours) and 10 times within 48 hours after administration in the pharmacokinetics study, and 24 tissue samples were obtained at 0.5 and 3 hours in the distribution study. Results—No adverse effects were observed in any of the mares after minocycline administration. The mean ± SD elimination half-life was 7.70 ± 1.91 hours. The total body clearance was 0.16 ± 0.04 L/h/kg, and the volume of distribution at steady state was 1.53 ± 0.09 L/kg. The percentage of plasma protein binding was 68.1 ± 2.6%. Plasma concentration of free minocycline was 0.12 μg/mL at 12 hours. Minocycline was not detected in brain tissue, CSF or aqueous humor at 0.5 hours; however, it was found in all tissues, except in the aqueous humor, at 3 hours. Conclusions and Clinical Relevance—Clearance of minocycline in healthy mares was greater than that reported for humans. For effective treatment of infections with common equine pathogens, it will be necessary to administer minocycline at a dosage of 2.2 mg/kg, IV, every 12 hours. This drug could be useful for infections in many tissues, including the CNS. The pharmacokinetic and tissue distribution data should aid in the appropriate use of minocycline in horses. (Am J Vet Res 2010;71:1062–1066)

6 January 2022 in Journal of Chromatography B
Verified
Journal Article
Closed access
HIHideaki Ishii
Hideaki Ishii
GLGary Ngai-Wa Leung
Gary Ngai-Wa Leung
SYShozo Yamashita
Shozo Yamashita
SNShun-Ichi Nagata
Shun-Ichi Nagata
AKAsuka Kushiro
Asuka Kushiro
IKIsao Kijima-Suda
Isao Kijima-Suda